Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
imipridone compounds including Modeyso™ (dordaviprone), a protease activator of the mitochondrial caseinolytic protease P (ClpP) and a dopamine D2 receptor (DRD2) inhibitor."Jazz is presenting research at AACR that highlights how we are advancing our oncology portfolio with pace and rigor to deliver differentiated
More news about: Jazz Pharmaceuticals plc
Oct 30, 2025, 17:31 ET Atypical Teratoid/Rhabdoid Tumor Treatment Market Shows Promising CAGR During the Forecast Period (2025-2034) with Growing Clinical Trials and R&D Initiatives | DelveInsight
patients. Additionally, the launch of emerging therapies such as PD-1 inhibitor (Nivolumab), Aurora A kinase inhibitor (Alisertib), C ClpP agonist and DRD2 antagonist (ONC206), among others, are further expected to propel the market.
More news about: DelveInsight Business Research, LLP